Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

Bell Potter analyst Baxter Kirk maintained a Hold rating on Austal today and set a price target of A$4.70. According to TipRanks, Kirk is a 4-star ...

Austal  (AUTLF) Gets a Hold from Bell Potter

Austal ( ($AU:ASB) ) has provided an update. Austal Limited will host an analyst and investor conference call on 31 August 2026 to discuss its fina...

Austal Sets Investor Call to Unveil FY2026 Results

Autolus Therapeutics (($AUTL)) has held its Q2 earnings call. Read on for the main highlights of the call. Autolus Therapeutics’ latest earnings ca...

Autolus Therapeutics Earnings Call Highlights Growth Momentum

In a report released today, Sam Teeger from Citi maintained a Hold rating on Austal , with a price target of A$5.07. According to TipRanks, Teeger ...

Citi Reaffirms Their Hold Rating on Austal  (AUTLF)

Wells Fargo analyst assigned a Buy rating to Autolus Therapeutics today and set a price target of $5.00. In a report released today, Goldman Sachs ...

Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Odyssey Therapeutics, Inc. (ODTX), Metagenomi, Inc. ...

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Metagenomi, Inc. (MGX) and Autolus Therapeutics (AUTL)

Analysts fell to the sidelines weighing in on Austal (AUTLF) and The Middleby (MIDD) with neutral ratings, indicating that the experts are neither ...

Analysts’ Top Industrial Goods Picks: Austal (AUTLF), The Middleby (MIDD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Autolus Therapeutics (AUTL) and Cronos Group (CRON) ...

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Cronos Group (CRON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Autolus Therapeutics (AUTL), Urogen Pharma (URGN) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Citi analyst Sam Teeger maintained a Sell rating on Austal today and set a price target of A$4.50. According to TipRanks, Teeger is an analyst with...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUTL	$2.24	-2.18%	1.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUTL	$2.24	-2.2%	1.84M
3
4
5
6

AUTL

Get Autolus Therapeutics plc Data in Excel

Get Autolus Therapeutics plc Data in Excel